Guardant Health Receives Accreditation from the College of American Pathologists

REDWOOD CITY, Calif., Sept. 15, 2014 /PRNewswire/ -- Guardant Health, a healthcare company focused on the development and commercialization of oncology diagnostic products, today announced that it has received accreditation by the College of American Pathologists (CAP) based on results of a recent on-site laboratory inspection.   The laboratory, based in Redwood City, is the leader in providing non-invasive, pan-cancer tumor genome sequencing with a simple blood draw.  This accreditation is awarded to facilities that meet the highest standards of quality in laboratory services.

"We are extremely proud of our team for accomplishing this major milestone in such a short period of time.  This accreditation reflects our commitment to the highest quality in cancer diagnostic testing for patients," said AmirAli Talasaz, PhD, President and Chief Technology Officer of Guardant Health. "Our mission is to provide best in class testing that generates actionable genomic information in real-time." 

The U.S. federal government recognizes the CAP Laboratory Accreditation Program as being equal-to or more-stringent than the government's own inspection program.  During the CAP inspection process, inspectors examine the laboratory's quality system and records.  Included in the inspection is the examination of laboratory staff qualifications, laboratory equipment, safety programs, and overall management practices.

About the College of American Pathologists
As the leading organization with more than 18,000 board-certified pathologists, the College of American Pathologists (CAP) serves patients, pathologists, and the public by fostering and advocating excellence in the practice of pathology and laboratory medicine worldwide. The CAP's Laboratory Improvement Programs, initiated 65 years ago, currently has customers in more than 100 countries, accrediting 7,600 laboratories and providing proficiency testing to 20,000 laboratories worldwide. Find more information about the CAP at www.cap.org.

About Guardant Health

Guardant Health is focused on developing breakthrough diagnostic technologies that possess the ability to transform cancer from a terminal illness to a manageable disease.  Guardant was founded in 2012 by a team of entrepreneurs with cutting edge expertise in next-generation sequencing, single-cell genomics and cancer diagnostics.  Guardant Health is committed to contributing a positive significant impact on patient health through cutting-edge technology that addresses long-standing unmet needs in oncology.    (www.guardanthealth.com)

About Guardant360®
Guardant360 is a best-in-class blood test that comprehensively sequences a patient's cancer in real-time to aid oncologists in making more informed, personalized treatment decisions without a tissue biopsy. Guardant360 is built on Digital Sequencing™, a proprietary method of capturing and genetically profiling trace fragments of tumor DNA that are shed into the blood stream ("cell-free DNA"), and provides high-fidelity tumor sequencing information at the single-molecule level.

Logo - http://photos.prnewswire.com/prnh/20140212/SF64352LOGO

SOURCE Guardant Health